PCSK9 and familial hyperaldosteronism: Moreover, this study revealed substantial deficits in the awareness of various clinical algorithms to diagnose patients with FH, cascade screening, specialist lipid services, and the existence of new, non-statin medications for FH, such as PCSK9 inhibitors.